PP-NAR4-CA-00087_05-2024 EN
References: 1. Antoniou T, Pritlove C, Shearer D, et al. A qualitative study of a publicly funded pharmacy-dispensed naloxone program. International Journal of Drug Policy. 2021:103146. 2. Centre for Addiction and Mental Health. Youth and Prescription Painkillers. Available at: https://www.camh.ca/en/health-info/guides-and-publications/youth-and-prescription-painkillers. 3. Government of Canada. About Opioids. Available at: https://www.canada.ca/en/health-canada/services/substance-use/problematic-prescription-drug-use/opioids/about.html. 4. Government of Canada. Canadian postsecondary education alcohol and drug use survey, 2019/2020. Available at: https://health-infobase.canada.ca/alcohol/cpads/. Accessed September 2, 2021. 5. Government of Canada. Opioid overdose. Available at: https://www.canada.ca/en/health-canada/services/substance-use/problematic-prescription-drug-use/opioids/overdose.html. 6. Mueller SR et al. Attitudes toward naloxone prescribing in clinical settings: a qualitative study of patients prescribed high dose opioids for chronic non-cancer pain. Gen Intern Med. 2016;32(3):277-283. 7. Ontario Pharmacists Association. Pharmacist clinical tool for initiating naloxone discussions. Available at: https://opatoday.com/wp-content/uploads/Practice/Tools/Naloxone/Pharmacist-Clinical-Tool-for-Initiating-Naloxone-Discussions.pdf. Accessed July 27, 2021. 8. Tsuyuki R et al. Canadian national consensus guidelines for naloxone prescribing by pharmacists. Canadian Pharmacists Journal. 2020;153(6):347-351.
PP-NAR4-CA-00087_05-2024 EN